再鼎医药（ZLAB）今日盘中大跌5.05%，引发市场关注。这一跌幅主要与公司近期发布的第三季度财报有关。
根据再鼎医药公布的2025年第三季度业绩报告，公司总收入为1.16亿美元，同比增长14%。尽管收入有所增长，但公司仍录得4880万美元的经营亏损。虽然亏损幅度较去年同期收窄28%，但仍未能扭亏为盈，这可能引发了投资者对公司盈利能力的担忧。
值得注意的是，再鼎医药将2025年全年总收入指引调整为至少4.6亿美元。这一调整可能被市场解读为公司对未来业绩预期的下调，进一步加剧了投资者的忧虑情绪。此外，公司现金及现金等价物、短期投资和流动受限制现金总计较上一季度有所下降，这也可能引发了市场对公司资金状况的关注。在生物科技股整体走弱的背景下，再鼎医药的股价承压下行。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.